Main Session: Best Practices in the Management of Infectious Complications for Patients with Cancer

How do biosimilars differ from generic drugs?

James S. Lewis, PharmD, FIDSA
Oregon Health and Science University

Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here